Charles River Laboratories (CRL): Valuation Perspectives After CFO Transition, Guidance Reaffirmation, and New Oncology Partnerships

Simply Wall St.

Sep 24, 2025

If you are eyeing Charles River Laboratories International (NYSE:CRL) right now, you are not alone. The surprise resignation of CFO Flavia H. Pease has put a major spotlight on the company’s ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2569747879"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569747879\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569747879?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2025-09-24 03:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569747879","market":"nz","top_or_hot":-1,"title":"Charles River Laboratories (CRL): Valuation Perspectives After CFO Transition, Guidance Reaffirmation, and New Oncology Partnerships","media":"Simply Wall St.","content":"<div>\n<p>If you are eyeing Charles River Laboratories International (NYSE:CRL) right now, you are not alone. The surprise resignation of CFO Flavia H. Pease has put a major spotlight on the company’s ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-crl-valuation-perspectives-after\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Charles River Laboratories (CRL): Valuation Perspectives After CFO Transition, Guidance Reaffirmation, and New Oncology Partnerships</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCharles River Laboratories (CRL): Valuation Perspectives After CFO Transition, Guidance Reaffirmation, and New Oncology Partnerships\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-24 03:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-crl-valuation-perspectives-after><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are eyeing Charles River Laboratories International (NYSE:CRL) right now, you are not alone. The surprise resignation of CFO Flavia H. Pease has put a major spotlight on the company’s ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-crl-valuation-perspectives-after\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRL","symbol_name":"查尔斯河","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-crl-valuation-perspectives-after","article_id":"2569747879","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-laboratories-crl-valuation-perspectives-after","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2569747879","pubTimestamp":1758656531,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are eyeing Charles River Laboratories International (NYSE:CRL) right now, you are not alone. The surprise resignation of CFO Flavia H. Pease has put a major spotlight on the company’s leadership, prompting plenty of armchair questions about what this means for the stock. Instead of letting uncertainty linger, Charles River quickly named an interim CFO and began a search for a permanent replacement. The company also took the opportunity to reaffirm its earnings guidance for the year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRL":"查尔斯河","BK4121":"生命科学工具和服务","BK7095":"多种金属与采矿","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4530":"医药外包概念","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","CRL.AU":"Comet Resources Ltd","BK4588":"碎股","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4585":"ETF&股票定投概念"},"translate_title":"Charles River Laboratories(CRL)：首席财务官过渡、指导方针重申和新的肿瘤学合作伙伴关系后的估值视角","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":1.5,"DCF":1,"CRL.AU":1.5},"content_text":"If you are eyeing Charles River Laboratories International (NYSE:CRL) right now, you are not alone. The surprise resignation of CFO Flavia H. Pease has put a major spotlight on the company’s leadership, prompting plenty of armchair questions about what this means for the stock. Instead of letting uncertainty linger, Charles River quickly named an interim CFO and began a search for a permanent replacement. The company also took the opportunity to reaffirm its earnings guidance for the year. With the addition of fresh collaborations in oncology research, it is clear that this is a company actively managing change rather than waiting for it. All these moves have come during a year where the stock’s trajectory has been anything but smooth. Shares have slid nearly 24% over the past 12 months, and despite some short-term upticks, the longer-term trend remains downward as investors digest both leadership shifts and evolving growth strategies. In the background, Charles River’s push into cutting-edge cell and gene therapies and strategic partnerships highlights an ongoing evolution in its business model, even as the market remains cautious about the near-term payoff. With major leadership changes, new alliances, and a reaffirmed outlook, is Charles River Laboratories trading at a discount to its true value or is its current price already factoring in everything the future could bring? AdvertisementMost Popular Narrative: 13.1% Undervalued According to the consensus narrative, Charles River Laboratories International is trading at a notable discount to its estimated fair value, based on medium-term growth and margin forecasts by analysts. This signals an undervaluation relative to their expectations for future earnings and operational improvements.   *The company's ongoing diversification and enhancement of its capabilities through investments in new approach methodologies (NAMs), automation, and digitalization positions it to benefit from industry shifts toward more complex and high-value testing. This also mitigates risks from regulatory and client preferences away from animal testing, improves operational efficiency, and supports future margin stability.*\n      Ever wonder what powers this undervalued call? The secret sauce is hidden in forward-looking financial targets that most investors rarely check twice. Bold projections on profits, sales growth, and future market multiples suggest a blueprint for a strong turnaround, but the real numbers may surprise you. Think the current share price is telling the full story? You might want to see how the narrative stacks up against the hard data, as some of these assumptions could redefine your expectations for Charles River’s next chapter. Result: Fair Value of $177.07 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, persistent price competition from global CRO rivals and ongoing softness in long-term study demand could still challenge the bullish narrative for Charles River. Find out about the key risks to this Charles River Laboratories International narrative. Another View: Discounted Cash Flow Perspective Taking a step back from analyst price targets, our SWS DCF model paints a different picture. This approach examines cash flows rather than market multiples and suggests Charles River could still be trading at a significant discount. Are market expectations missing something in these cash flow projections, or are there hidden risks ahead? Look into how the SWS DCF model arrives at its fair value. CRL Discounted Cash Flow as at Sep 2025 Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Charles River Laboratories International for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.\n Build Your Own Charles River Laboratories International Narrative If you think the story runs deeper or want to dig into the numbers on your own terms, you can craft a custom narrative in just minutes: Do it your way. A great starting point for your Charles River Laboratories International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Looking for More Smart Investment Opportunities? Why limit yourself to one story? Start broadening your horizon and set yourself up for the next breakthrough by using our powerful stock screener. Miss this and you could miss the trends reshaping the market before your eyes.  Power up your search for hidden value by targeting companies with strong cash flows and promising upside through our undervalued stocks based on cash flows screen. Capitalize on booming breakthroughs in artificial intelligence by filtering for firms disrupting industries with game-changing AI tech using AI penny stocks. Supercharge your portfolio with stocks offering impressive yields and balanced fundamentals, starting with dividend stocks with yields > 3%.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}